Cell salvage in hip and knee arthroplasty

A meta-analysis of randomized controlled trials

Review (2015)

Authors

Leti van Bodegom-Vos Leiden University Medical Center
Veronique M.A. Voorn Leiden University Medical Center
Cynthia So-Osman Sanquin Research
Thea P.M.Vliet Vlieland Leiden University Medical Center
Albert Dahan Leiden University Medical Center
Ankie W.M.M. Koopman-Van Gemert Albert Schweitzer Hospital, Dordrecht
S.B.W. Vehmeijer Reinier de Graaf Gasthuis
R.G.H.H. Nelissen Leiden University Medical Center
P.J. Marang-van de Mheen Leiden University Medical Center
Affiliation
External organisation
More Info
expand_more

Published Date

2015

Language

English

Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Affiliation

External organisation

Abstract

Background: Cell salvage is used to reduce allogeneic red blood-cell (RBC) transfusions in total hip arthroplasty (THA) and total knee arthroplasty (TKA). We performed a meta-analysis to assess the effectiveness of cell salvage to reduce transfusions in THA and TKA separately, and to examine whether recent trials change the conclusions frompreviousmeta-analyses. Methods: We searched MEDLINE through January 2013 for randomized clinical trials evaluating the effects of cell salvage in THA and TKA. Trial results were extracted using standardized forms and pooled using a random-effects model. Methodological quality of the trials was evaluated using the Cochrane Collaboration's tool for risk-of-bias assessment. Results: Forty-three trials (5631 patients) were included. Overall, cell salvage reduced the exposure to allogeneic RBC transfusion in THA (risk ratio [RR], 0.66; 95% confidence interval [CI], 0.51 to 0.85) and TKA (RR, 0.51; 95% CI, 0.39 to 0.68). However, trials published in 2010 to 2012, with a lower risk of bias, showed no significant effect of cell salvage in THA (RR, 0.82; 95% CI, 0.66 to 1.02) and TKA (RR, 0.91; 95% CI, 0.63 to 1.31), suggesting that the treatment policy regarding transfusion may have changed over time. Conclusions: Looking at all trials, cell salvage still significantly reduced the RBC exposure rate and the volume of RBCs transfused in both THA and TKA. However, in trials published more recently (2010 to 2012), cell salvage reduced neither the exposure rate nor the volume of RBCs transfused in THA and TKA, most likely explained by changes in blood transfusion management. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.